The short version of Reference standard fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-10. Anything still debated is marked as such rather than presented as settled.
Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, its terminal amino group, and a deprotonated amide nitrogen, creating a stable chelate ring. The resulting complex carries a distinctive blue to blue-violet color, which arises from copper d-d electronic transitions. In the solid state it is usually handled as a powder, while in solution the complex can dissociate and re-form depending on pH and competing ligands. The name copper tripeptide-1 is widely used in ingredient listings.
The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.
The peptide was first isolated from human albumin in 1973 by Loren Pickart, who later described its copper-binding behavior. Early work linked the complex to wound healing and tissue remodeling. Plasma levels of GHK decline with age, a pattern that stimulated interest in topical and supplemental applications. Researchers have reported that the tripeptide influences collagen synthesis, antioxidant defense, and inflammatory signaling in cell and animal models. Human clinical evidence remains limited and often relies on small studies.
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H24N6O4 | Free tripeptide, without copper |
| Molecular weight | About 340 g/mol | Peptide portion only |
| Appearance | Blue to violet powder | Color from copper coordination |
| Solubility | Soluble in water | pH influences dissolution |
| Common synonyms | Copper tripeptide-1, Cu-GHK | Seen on ingredient labels |
Characterizing GHK-Cu requires methods that distinguish the intact complex from free peptide and unbound copper. UV-visible absorption around 600 nm provides a rapid check for copper coordination, while circular dichroism reports on peptide secondary structure. Mass spectrometry confirms the peptide mass and can detect copper adducts under carefully controlled conditions. Electron paramagnetic resonance is particularly informative for Cu(II) because it reveals the ligand field symmetry. No single technique fully defines the complex, so laboratories combine orthogonal methods.
Stability of GHK-Cu in solution depends on pH, temperature, buffer composition, and oxygen exposure. The copper center can undergo reduction or dissociation, especially in the presence of strong metal chelators such as EDTA. Aqueous solutions are often prepared fresh or stored frozen to limit degradation. Lyophilized solid is more stable than liquid formulations, but it can absorb moisture and should be kept dry. Light exposure may also affect copper complexes, though the effect is often modest.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Laboratory characterization of GHK-Cu typically combines separation, spectroscopic, and elemental techniques. Reverse-phase high-performance liquid chromatography is widely used to assess peptide purity, often with ultraviolet detection near the copper-related absorption band or with mass spectrometry for identity confirmation. Because the molecule contains copper, elemental methods such as inductively coupled plasma mass spectrometry or atomic absorption spectroscopy are used to quantify metal content and confirm stoichiometry. No single universal pharmacopeial monograph exists for GHK-Cu. Laboratories therefore validate their own methods, and reported purity values depend on the chosen assay and calibration standards.
Stability of GHK-Cu is influenced by light, oxygen, moisture, pH, and temperature. Solid material is generally kept desiccated and frozen to reduce hydrolysis and oxidation, while aqueous solutions are best prepared fresh or stored cold in aliquots. Repeated freeze-thaw cycles can promote aggregation, precipitation, or peptide degradation. Copper coordination may change under strongly acidic or alkaline conditions, potentially altering the complex's spectroscopic properties. Published long-term stability data for specific matrices, such as cosmetic emulsions or biological buffers, are limited, so shelf-life claims should be treated as formulation-specific rather than universal.
Quality control for GHK-Cu relies on documentation and independent testing rather than a single accepted standard. A certificate of analysis may report peptide purity, copper content, residual solvents, water content, and microbial limits, but the underlying methods and acceptance criteria vary by supplier. Verification can include mass confirmation, amino acid analysis, and comparison with a reference standard when one is available. Open questions include how different copper-binding modes or peptide isomers affect measured activity and whether conventional purity assays capture those differences. Buyers of research-grade material typically need to request raw data rather than rely solely on a summary certificate.
Solid GHK-Cu is usually supplied as a lyophilized powder and is kept cold and dry. Moisture, light, and repeated temperature cycling shorten its useful life in the laboratory. In aqueous solution the complex undergoes slow hydrolysis of the peptide backbone and gradual loss of coordinated copper. Buffers containing strong chelators, such as EDTA, compete for the metal and strip it from the peptide. Working solutions are therefore prepared shortly before use, and leftover liquid is not returned to the stock container.
Identity and purity are established with a combination of chromatographic and spectroscopic techniques. Reversed-phase high-performance liquid chromatography separates the intact complex from peptide fragments and free copper, and the elution profile yields a purity estimate. Mass spectrometry gives the mass of the intact species and exposes degradation products. Ultraviolet-visible spectroscopy displays a broad absorption band in the visible region that is characteristic of the copper center. Nuclear magnetic resonance is less informative here, because the paramagnetic metal broadens signals and complicates spectral interpretation.
Copper content is measured separately, since a peptide assay alone does not report the metal-to-peptide ratio. Elemental techniques such as inductively coupled plasma optical emission spectroscopy quantify copper after acid digestion of the sample. The result is compared with the theoretical value for a one-to-one complex, and a shortfall indicates free peptide or partial dissociation. Suppliers differ in how they state purity, as some quote peptide content and others quote the whole complex. A defined stoichiometry therefore requires both a peptide assay and a copper assay.
== Solute carrier family examples == (1) high affinity glutamate and neutral amino acid transporter (3) Heavy subunits of heteromeric amino acid transporters (6) Bacterial Leucine Transporter (LeuT) (7) cationic amino acid transporter/glycoprotein-associated (15) proton oligopeptide cotransporter (17) vesicular glutamate transporter (18) vesicular amine transporter (25) some mitochondrial carriers (26) multifunctional anion exchanger (32) vesicular inhibitory amino acid transporter (36) proton-coupled amino acid transporter (38) System A & N, sodium-coupled neutral amino acid transporter
==== Fallout from the affair ==== Unlike when Peter Thorneycroft (Chancellor of the Exchequer) resigned in 1958 or Lord Carrington (Foreign Secretary) in 1982, Heseltine's junior ministers Norman Lamont and John Lee did not resign with him. Heseltine was portrayed by Spitting Image as a swivel-eyed lunatic holding a toy helicopter. Brittan had to resign, partly as a result of fallout from the leak of the Mayhew letter, and partly because of his failure to give an entirely truthful answer to the House of Commons about Heseltine's accusation that he had pressured British Aerospace to withdraw from the European Consortium. Thatcher survived the Westland debate on 27 January, aided by a poor and long-winded speech by Opposition Leader Neil Kinnock. Sikorsky bought Westland. Up until Westland, Thatcher had approved of most of what Heseltine had done, even though their politics were rather different. Heseltine and Thatcher had quarrelled openly over a question of relations between Britain and the European Community (as it then was). Apart from the clash of personalities, and the escalation of small issues into bigger issues, it has been suggested that Heseltine, concerned at impending Defence cuts in 1986, and worried that Thatcher was unlikely to promote him further, was looking for an excuse for a resignation, which would put him in good stead to be elected party leader after, as seemed likely at the time, the Conservatives would lose the next election due by summer 1988.
=== Novels === Anecdotes persanes, dédiées au roy (1727 - English translation: Persian Anecdotes, dedicated to the King) Anecdotes, ou Histoire secrette de la maison ottomane (1722 - English translation: Anecdotes, or Secret History of the Ottoman House) Crémentine, reine de Sanga; histoire indienne (1727 - English translation: Creatine, Queen of Sanga: Indian History) Entretiens nocturnes de Mercure et de La Renommée, au jardin des Thuilleries (1714 - English translation: Nocturnal interviews of Mercury and La Renommée in the Tuileries Garden.) Histoire de Jean de Calais, roi de Portugal, ou, La vertu recompensee (1731 - English translation: The History of Jean de Calais, King of Portugal, or Virtue Rewarded) Histoire d'Osman premier du nom, XIXe empereur des Turcs, et de l'impératrice Aphendina Ashada (1734 - English translation: History of Osman, first of the name, XIXth emperor of the Turks, and of the empress Aphendina Ashada) Histoire du comte d’Oxfort, de Miledy d’Herby, d’Eustache de Saint-Pierre et de Beatrix de Guines au siège de la ville de Calais, sous le règne de Philippe de Valois, roi de France & de Navarré, en 1346 & 1347(1765 - English translation: History of the Count of Oxford, of Miledy of Herby, of Eustace of St. Peter and of Beatrix of Guines at the siege of the city of Calais, under the reign of Philip of Valois, King of France and of Navarre, in 1346 and 1347) Histoire secrette de la conqueste de Grenade (1723 - English translation: The secret history of the conquest of Granada) Histoires du comte d'Oxfort, de Miledy d'Herby, d'Eustache de S.
== Early life == Khloé Alexandra Kardashian was born on June 27, 1984, in Los Angeles, California, to Kris (née Houghton), a homemaker, and Robert, an attorney. She has two older sisters, Kourtney and Kim, and a younger brother, Rob. Their mother is of Dutch, English, Irish and Scottish ancestry, while their father was a third-generation Armenian-American. After her parents divorced in 1991, her mother married 1976 Summer Olympics decathlon winner Caitlyn Jenner (then Bruce) in 1991. Through their marriage, Kardashian gained stepbrothers Burt, Brandon, and Brody; stepsister Casey; and half-sisters Kendall and Kylie. In 1994, her father garnered public attention as a defense lawyer for football player O. J. Simpson during his murder trial. Kardashian went to Bel Air Prep, Saint Martin of Tours School, Daniel Webster Middle School, A.E. Wright Middle School, and Montclair Prep. As a teenager, she briefly attended Marymount High School, a Roman Catholic all-girls' school in Los Angeles. She left the high school and enrolled in Alexandria Academy, an alternative one-to-one school, after her sisters' graduations, later saying "there was no reason for me to stay" since she "felt like I didn't have any friends." She graduated with honors a year early at age 17. Before her family reality TV show, Kardashian worked as Nicole Richie's assistant.
Sources: en.wikipedia.org
== Mechanism == Pyridoxine is in the vitamin B family of vitamins. It is required by the body to make amino acids, carbohydrates, and lipids. Sources in the diet include fruit, vegetables, and grain. It is also required for muscle phosphorylase activity associated with glycogen metabolism.
Such antifungal action when other drugs deem inefficient is characteristic of lactoferrin and is especially valuable for HIV-infected patients. Contrary to the antiviral and antibacterial actions of lactoferrin, very little is known about the mechanism of its antifungal action. Lactoferrin seems to bind the plasma membrane of C. albicans inducing an apoptotic-like process.
After completing her PhD, Dayhoff studied electrochemistry under Duncan A. MacInnes at the Rockefeller Institute from 1948 to 1951. In 1952, she moved to Maryland with her family and later received research fellowships from the University of Maryland (1957–1959), working on a model of chemical bonding with Ellis Lippincott. At Maryland, she gained her first exposure to a new high-speed computer, the IBM model 7094. After this ended, she joined the National Biomedical Research Foundation in 1960 as associate director (a position she held for 21 years). At the NBRF, she began to work with Robert Ledley, a dentist who had obtained a degree in physics and become interested in the possibilities of applying computational resources to biomedical problems. He had authored one of the earliest studies of biomedical computation, "Report on the Use of Computer in Biology and Medicine." With their combined expertise, they published a paper in 1962 entitled "COMPROTEIN: A computer program to aid primary protein structure determination" that described a "completed computer program for the IBM 7090" that aimed to convert peptide digests to protein chain data. They actually began this work in 1958, but were not able to start programming until late 1960.
Sources: en.wikipedia.org
It is a complex of the tripeptide glycyl-L-histidyl-L-lysine with a copper(II) ion. The peptide coordinates the metal through its histidine, amino terminus, and an amide nitrogen. It is often listed simply as copper tripeptide-1.
The peptide and its copper form have been detected in human plasma, saliva, and urine. Early reports describe levels that fall with age. The functional meaning of these pools is still debated.
Chromatographic separation gives peptide purity, often reported as a percentage. Copper content is checked by a separate elemental method. Moisture and counter-ions may be reported as well.
GHK is the free tripeptide, while GHK-Cu includes a bound copper(II) ion. The copper complex is the form most often studied for skin and wound-related activity. The two names are sometimes used interchangeably in product labeling, but they refer to distinct chemical species.